B
AVDL

Braidwell’s Avadel Pharmaceuticals AVDL Stock Holding History

Braidwell’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,105,726
Closed -$43.2M – 65
2024
Q4 		$43.2M Buy
4,105,726
+716,787
+21% +$8.7M 1.28% 33
2024
Q3 		$44.4M Buy
3,388,939
+490,300
+17% +$7.47M 1.26% 34
2024
Q2 		$40.8M Buy
2,898,639
+230,090
+9% +$3.75M 1.28% 34
2024
Q1 		$45.1M Buy
+2,668,549
New +$39.7M 1.45% 29

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Braidwell's AVDL Position: Q1 2025 in Review

Braidwell sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 4,105,726 shares — an estimated $43.2M sold.

Braidwell first reported a position in AVDL in Q1 2024 and held it in 4 quarters. The position peaked at $45.1M in Q1 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Braidwell reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Braidwell sold 4,105,726 Avadel Pharmaceuticals shares in Q1 2025, an estimated $43.2M.
  • Braidwell first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Braidwell's Avadel Pharmaceuticals position peaked at $45.1M in Q1 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.